Literature DB >> 22389450

A galectin-3-dependent pathway upregulates interleukin-6 in the microenvironment of human neuroblastoma.

Ayaka M Silverman1, Rie Nakata, Hiroyuki Shimada, Richard Sposto, Yves A DeClerck.   

Abstract

Interleukin-6 (IL-6) is a pleiotropic cytokine with a broad range of physiologic and pathologic functions. Because in cancer, IL-6 contributes to a microenvironment that promotes tumor cell survival, angiogenesis, and inflammation, understanding the mechanism responsible for its production is important. In neuroblastoma, the second most common solid tumor in children, IL-6 is produced not by tumor cells but by stromal cells such as monocytes and bone marrow mesenchymal stem cells (BMMSC). Here we show that the production of IL-6 in BMMSCs is in part stimulated by galectin-3 binding protein (Gal-3BP) secreted by neuroblastoma cells. We identified a distal region of the IL-6 promoter that contains 3 CCATT/enhancer binding protein (C/EBP) binding domains involved in the transcriptional upregulation of IL-6 by Gal-3BP. Gal-3BP interacted with Galectin-3 (Gal-3) present in BMMSCs, and a Gal-3BP/Gal-3/Ras/MEK/ERK signaling pathway was responsible for the transcriptional upregulation of IL-6 in BMMSCs in which Gal-3 has a necessary function. In support of the role of this pathway in human neuroblastoma tumors, Gal-3BP was found to be present in tumor cells and in the adjacent extracellular matrix of 96% of 78 primary neuroblastoma tumor samples examined by immunohistochemistry. Considering the protumorigenic function of IL-6 in cancer, this tumor cell-stromal cell interactive pathway could be a target for anticancer therapy. ©2012 AACR

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22389450      PMCID: PMC3815584          DOI: 10.1158/0008-5472.CAN-11-2165

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  37 in total

1.  Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.

Authors:  Y Nefedova; T H Landowski; W S Dalton
Journal:  Leukemia       Date:  2003-06       Impact factor: 11.528

2.  Evidence for the involvement of galectin-3 in mesenchymal stem cell suppression of allogeneic T-cell proliferation.

Authors:  M Sioud; A Mobergslien; A Boudabous; Y Fløisand
Journal:  Scand J Immunol       Date:  2010-04       Impact factor: 3.487

3.  Interdependence between cytokines and cell adhesion molecules to induce interleukin-6 production by stromal cells in myeloma.

Authors:  X Thomas; B Anglaret; J P Magaud; J Epstein; E Archimbaud
Journal:  Leuk Lymphoma       Date:  1998-12

4.  Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee.

Authors:  H Shimada; I M Ambros; L P Dehner; J Hata; V V Joshi; B Roald
Journal:  Cancer       Date:  1999-07-15       Impact factor: 6.860

5.  Bone marrow mesenchymal stem cells provide an alternate pathway of osteoclast activation and bone destruction by cancer cells.

Authors:  Yasuyoshi Sohara; Hiroyuki Shimada; Cedric Minkin; Anat Erdreich-Epstein; Jan A Nolta; Yves A DeClerck
Journal:  Cancer Res       Date:  2005-02-15       Impact factor: 12.701

6.  Role of 90K protein in asthma and TH2-type cytokine expression.

Authors:  Omer Kalayci; Esra Birben; Nicola Tinari; Tsuyoshi Oguma; Stefano Iacobelli; Craig M Lilly
Journal:  Ann Allergy Asthma Immunol       Date:  2004-11       Impact factor: 6.347

7.  Mac-2 binding protein is a cell-adhesive protein of the extracellular matrix which self-assembles into ring-like structures and binds beta1 integrins, collagens and fibronectin.

Authors:  T Sasaki; C Brakebusch; J Engel; R Timpl
Journal:  EMBO J       Date:  1998-03-16       Impact factor: 11.598

8.  The secreted tumor-associated antigen 90K is a potent immune stimulator.

Authors:  A Ullrich; I Sures; M D'Egidio; B Jallal; T J Powell; R Herbst; A Dreps; M Azam; M Rubinstein; C Natoli
Journal:  J Biol Chem       Date:  1994-07-15       Impact factor: 5.157

9.  Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas.

Authors:  H Shimada; J Chatten; W A Newton; N Sachs; A B Hamoudi; T Chiba; H B Marsden; K Misugi
Journal:  J Natl Cancer Inst       Date:  1984-08       Impact factor: 13.506

10.  Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells.

Authors:  Yeong-Shiau Pu; Tzyh-Chyuan Hour; Shuang-En Chuang; Ann-Lii Cheng; Ming-Kuen Lai; Min-Liang Kuo
Journal:  Prostate       Date:  2004-07-01       Impact factor: 4.104

View more
  34 in total

1.  Interaction between bone marrow stromal cells and neuroblastoma cells leads to a VEGFA-mediated osteoblastogenesis.

Authors:  Josephine H HaDuong; Laurence Blavier; Sanjeev K Baniwal; Baruch Frenkel; Jemily Malvar; Vasu Punj; Richard Sposto; Yves A DeClerck
Journal:  Int J Cancer       Date:  2015-02-21       Impact factor: 7.396

Review 2.  Extracellular galectins as controllers of cytokines in hematological cancer.

Authors:  Monica Gordon-Alonso; Annika M Bruger; Pierre van der Bruggen
Journal:  Blood       Date:  2018-06-06       Impact factor: 22.113

3.  The role of galectin-3 and galectin-3-binding protein in venous thrombosis.

Authors:  Elise P DeRoo; Shirley K Wrobleski; Evelyn M Shea; Ramsey K Al-Khalil; Angela E Hawley; Peter K Henke; Daniel D Myers; Thomas W Wakefield; Jose A Diaz
Journal:  Blood       Date:  2014-11-26       Impact factor: 22.113

4.  Lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a tumor-associated immunomodulatory ligand for CD33-related Siglecs.

Authors:  Heinz Läubli; Frederico Alisson-Silva; Michal A Stanczak; Shoib S Siddiqui; Liwen Deng; Andrea Verhagen; Nissi Varki; Ajit Varki
Journal:  J Biol Chem       Date:  2014-10-15       Impact factor: 5.157

5.  Association between circulating galectin-3 levels and the immunological, inflammatory and nutritional parameters in patients with colorectal cancer.

Authors:  Tatsuo Shimura; Masahiko Shibata; Kenji Gonda; Takahiro Nakajima; Shun Chida; Masaru Noda; Satoshi Suzuki; Izumi Nakamura; Shinji Ohki; Seiichi Takenoshita
Journal:  Biomed Rep       Date:  2016-05-30

Review 6.  More than the genes, the tumor microenvironment in neuroblastoma.

Authors:  Lucia Borriello; Robert C Seeger; Shahab Asgharzadeh; Yves A DeClerck
Journal:  Cancer Lett       Date:  2015-11-17       Impact factor: 8.679

Review 7.  Extrinsic and Intrinsic Mechanisms by Which Mesenchymal Stem Cells Suppress the Immune System.

Authors:  Vivien J Coulson-Thomas; Yvette M Coulson-Thomas; Tarsis F Gesteira; Winston W-Y Kao
Journal:  Ocul Surf       Date:  2016-01-12       Impact factor: 5.033

8.  Critical role of STAT3 in IL-6-mediated drug resistance in human neuroblastoma.

Authors:  Tasnim Ara; Rie Nakata; Michael A Sheard; Hiroyuki Shimada; Ralf Buettner; Susan G Groshen; Lingyun Ji; Hua Yu; Richard Jove; Robert C Seeger; Yves A DeClerck
Journal:  Cancer Res       Date:  2013-04-30       Impact factor: 12.701

Review 9.  Physiological, Tumor, and Metastatic Niches: Opportunities and Challenges for Targeting the Tumor Microenvironment.

Authors:  Meera Murgai; Amber Giles; Rosandra Kaplan
Journal:  Crit Rev Oncog       Date:  2015

10.  Immunosuppressive microenvironment in neuroblastoma.

Authors:  Vito Pistoia; Fabio Morandi; Giovanna Bianchi; Annalisa Pezzolo; Ignazia Prigione; Lizzia Raffaghello
Journal:  Front Oncol       Date:  2013-06-26       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.